Detalhe da pesquisa
1.
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis.
Clin Exp Dermatol
; 48(6): 623-630, 2023 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36794376
2.
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study.
Clin Exp Dermatol
; 48(7): 765-769, 2023 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36928932
3.
The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis.
J Am Acad Dermatol
; 87(6): 1455-1458, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35872261
4.
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study.
Dermatol Ther (Heidelb)
; 13(6): 1255-1264, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37170057